Takeda taps Protagonist before it’s Verified
Rusfertide’s big readout will now not come until 2025.
Carvykti joins Abecma in adcom limbo
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.
T-cell engagers enter new pivotal studies
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
J&J deal cements Ambrx’s transformation
Ambrx’s PSMA-targeting ADC generated puzzling data at ESMO, but J&J has seen enough to launch a premium-priced buyout.
KRAS crowding continues
Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.
Christmas holiday round-up
As the biotech markets turned bullish the sector’s ups and downs continued.
A new order in BTK inhibition
Imbruvica faces challenges on multiple fronts.
Interview – Kura’s combo test nears
Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?
